Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol
Quesada-Gomez et al.,
Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol,
Nutrients, doi:10.3390/nu14132716 (Review)
Review of the use of calcifediol for COVID-19. Authors note several advantages of calcifediol vs. cholecalciferol: calcifediol induces a more rapid increase in circulating 250HD; calcifediol is more potent than cholecalciferol; calcifediol has a higher rate of intestinal absorption; and calcifediol has a linear dose-response curve, independent of initial serum levels.
Authors note that the available data strongly and consistently suggest that treatment with calcifediol can reduce the severity of COVID-19; and that calcifediol is cost-effective and widely available, without significant adverse effects. Authors propose to use calcifediol for the rapid correction of vitamin D deficiency in all patients in the early stages of COVID-19.
Quesada-Gomez et al., 29 Jun 2022, peer-reviewed, 7 authors.
Contact:
jmquesada@uco.es (corresponding author), md1lomij@uco.es, bb1cadia@uco.es, xnogues@psmar.cat, marenca@gmail.com, joseluismansur@yahoo.com.ar, roger.bouillon@kuleuven.be.
Abstract: nutrients
Review
Vitamin D Endocrine System and COVID-19: Treatment
with Calcifediol
Jose Manuel Quesada-Gomez 1,2, *, José Lopez-Miranda 1,3,4 , Marta Entrenas-Castillo 5 ,
Antonio Casado-Díaz 1,2,6 , Xavier Nogues y Solans 2,7 , José Luis Mansur 8 and Roger Bouillon 9, *
1
2
3
4
5
6
7
8
9
*
Citation: Quesada-Gomez, J.M.;
Lopez-Miranda, J.; Entrenas-Castillo,
M.; Casado-Díaz, A.; Nogues y
Solans, X.; Mansur, J.L.; Bouillon, R.
Vitamin D Endocrine System and
COVID-19: Treatment with
Calcifediol. Nutrients 2022, 14, 2716.
https://doi.org/10.3390/
nu14132716
Academic Editor: Federica I. Wolf
Received: 22 April 2022
Accepted: 27 June 2022
Published: 29 June 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.
Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía,
14004 Córdoba, Spain; md1lomij@uco.es (J.L.-M.); bb1cadia@uco.es (A.C.-D.)
Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES),
Instituto de Salud Carlos III, 28029 Madrid, Spain; xnogues@psmar.cat
Departamento de Medicina Interna, Hospital Universitario Reina Sofía, 14004 Córdoba, Spain
CIBER Fisiopatologia Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain
Hospital QuirónSalud, 14004 Córdoba, Spain; marenca@gmail.com
Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Reina Sofía,
14004 Córdoba, Spain
Internal Medicine Department, IMIM (Hospital del Mar Medical Research Institute), Hospital del Mar,
08003 Barcelona, Spain
Centro de Endocrinología y Osteoporosis La Plata, Buenos Aires B1902ADQ, Argentina;
joseluismansur@yahoo.com.ar
Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism,
Catholic University of Leuven, 3000 Leuven, Belgium
Correspondence: jmquesada@uco.es (J.M.Q.-G.); roger.bouillon@kuleuven.be (R.B.)
Abstract: The COVID-19 pandemic is the greatest challenge facing modern medicine and public
health systems. The viral evolution of SARS-CoV-2, with the emergence of new variants with
in-creased infectious potential, is a cause for concern. In addition, vaccination coverage remains
in-sufficient worldwide. Therefore, there is a need to develop new therapeutic options, and/or to optimize the repositioning of drugs approved for other indications for COVID-19. This may include the
use of calcifediol, the prohormone of the vitamin D endocrine system (VDES) as it may have potential
useful effects for the treatment of COVID-19. We review the aspects associating COVID-19 with
VDES and the potential use of calcifediol in COVID-19. VDES/VDR stimulation may enhance innate
antiviral effector mechanisms, facilitating the induction of antimicrobial peptides/autophagy, with a
critical modulatory role in the subsequent host reactive hyperinflammatory phase during COVID-19:
By decreasing the cytokine/chemokine storm, regulating the renin–angiotensin–bradykinin system
(RAAS), modulating neutrophil activity and maintaining the integrity of the pulmonary epithelial
barrier, stimulating epithelial repair, and directly and indirectly decreasing the increased coagulability and prothrombotic tendency associated with severe COVID-19 and its..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit